# Learning Resources for Clinical Variant Annotation

This document provides additional learning resources to deepen your understanding of clinical variant interpretation and reporting.

## Recommended Learning Path

### Week 1: Variant Annotation Fundamentals

1. **VEP Tutorial**
   - [Ensembl VEP Documentation](https://www.ensembl.org/info/docs/tools/vep/index.html)
   - [VEP Web Interface](https://www.ensembl.org/Tools/VEP)

2. **Consequence Types**
   - [Sequence Ontology](http://www.sequenceontology.org/)
   - [Ensembl Consequence Types](https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html)

### Week 2: Clinical Databases

1. **ClinVar**
   - [ClinVar Homepage](https://www.ncbi.nlm.nih.gov/clinvar/)
   - [ClinVar Submission Guidelines](https://www.ncbi.nlm.nih.gov/clinvar/docs/submit/)

2. **gnomAD**
   - [gnomAD Browser](https://gnomad.broadinstitute.org/)
   - [gnomAD Paper](https://www.nature.com/articles/s41586-020-2308-7)

### Week 3: ACMG Guidelines

1. **Variant Classification**
   - [ACMG Standards and Guidelines](https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Practice-Guidelines.aspx)
   - [2015 ACMG-AMP Guidelines Paper](https://www.nature.com/articles/gim201530)

2. **Clinical Interpretation**
   - [ClinGen](https://clinicalgenome.org/)
   - [InterVar](https://wintervar.wglab.org/)

## Key Concepts to Master

### Variant Effect Prediction

| Tool | Predicts | Interpretation |
|------|----------|----------------|
| **SIFT** | Amino acid substitution impact | Score <0.05 = deleterious |
| **PolyPhen-2** | Protein structure/function | Score >0.85 = probably damaging |
| **CADD** | Deleteriousness | Score >20 = top 1% most deleterious |
| **REVEL** | Pathogenicity (ensemble) | Score >0.5 = likely pathogenic |

### Population Frequency Interpretation

| Frequency | Interpretation | ACMG Criteria |
|-----------|----------------|---------------|
| >5% | Too common for rare disease | BA1 (Benign standalone) |
| >1% | Likely benign | BS1 (Benign strong) |
| <0.01% | Rare, could be pathogenic | PM2 (Pathogenic moderate) |
| Absent | Very rare, supports pathogenicity | PM2 |

### ACMG Evidence Categories

**Pathogenic Evidence:**
| Code | Strength | Description |
|------|----------|-------------|
| PVS1 | Very Strong | Null variant in gene where LOF is mechanism |
| PS1 | Strong | Same amino acid change as established pathogenic |
| PS3 | Strong | Functional studies support damaging effect |
| PM1 | Moderate | Located in mutational hot spot |
| PM2 | Moderate | Absent from population databases |
| PP3 | Supporting | Computational evidence supports deleterious |

**Benign Evidence:**
| Code | Strength | Description |
|------|----------|-------------|
| BA1 | Standalone | Allele frequency >5% |
| BS1 | Strong | Allele frequency greater than expected |
| BS3 | Strong | Functional studies show no damaging effect |
| BP4 | Supporting | Computational evidence suggests no impact |

## Practice Exercises

### Exercise 1: Manual Variant Interpretation

1. Go to [ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/)
2. Search for "BRCA1 c.5266dupC"
3. Review the clinical significance and evidence
4. Identify which ACMG criteria apply

### Exercise 2: VEP Annotation

1. Go to [VEP Web Interface](https://www.ensembl.org/Tools/VEP)
2. Enter variant: `17 43092919 . G A`
3. Review the annotation results
4. Identify the most severe consequence

### Exercise 3: Population Frequency Analysis

1. Go to [gnomAD](https://gnomad.broadinstitute.org/)
2. Search for a variant of interest
3. Compare frequencies across populations
4. Determine if frequency supports pathogenicity

## Interview Deep Dives

### Topic 1: Why use multiple annotation sources?

**Key Points:**
- No single database is complete
- Cross-validation improves accuracy
- Different databases have different strengths
- ClinVar for clinical significance
- gnomAD for population frequencies
- VEP for functional predictions

### Topic 2: How do you handle conflicting classifications?

**Key Points:**
- Review the evidence behind each classification
- Consider the review status (star rating)
- Look at the number and quality of submissions
- Apply ACMG criteria independently
- Document your reasoning

### Topic 3: What are the limitations of computational predictions?

**Key Points:**
- Training data bias
- Cannot predict all functional effects
- Tissue-specific effects not captured
- Regulatory variants poorly predicted
- Should be used as supporting evidence only

## Clinical Reporting Best Practices

### Report Structure

1. **Patient Demographics** (de-identified for research)
2. **Test Information** (methodology, limitations)
3. **Results Summary** (positive/negative)
4. **Variant Details** (gene, change, classification)
5. **Interpretation** (clinical significance)
6. **Recommendations** (follow-up actions)
7. **Methodology** (technical details)
8. **Limitations** (what the test cannot detect)

### Writing Clinical Interpretations

**DO:**
- Use clear, unambiguous language
- Cite evidence for classifications
- Provide actionable recommendations
- Include genetic counseling referral

**DON'T:**
- Use jargon without explanation
- Make definitive statements for VUS
- Omit important limitations
- Forget to mention family testing

## AWS Deployment for HIPAA

### Architecture Components

```
┌─────────────────────────────────────────────────────┐
│                    AWS Cloud                         │
│  ┌─────────────────────────────────────────────┐   │
│  │              VPC (Private)                    │   │
│  │  ┌─────────┐  ┌─────────┐  ┌─────────────┐  │   │
│  │  │ Lambda  │  │   ECS   │  │     RDS     │  │   │
│  │  │(Pipeline)│  │(Workers)│  │ (Encrypted) │  │   │
│  │  └────┬────┘  └────┬────┘  └──────┬──────┘  │   │
│  │       │            │              │          │   │
│  │  ┌────┴────────────┴──────────────┴────┐    │   │
│  │  │           S3 (SSE-KMS)              │    │   │
│  │  └─────────────────────────────────────┘    │   │
│  └─────────────────────────────────────────────┘   │
│                                                     │
│  ┌─────────────┐  ┌─────────────┐  ┌───────────┐  │
│  │ CloudTrail  │  │     KMS     │  │    IAM    │  │
│  │  (Audit)    │  │   (Keys)    │  │  (Access) │  │
│  └─────────────┘  └─────────────┘  └───────────┘  │
└─────────────────────────────────────────────────────┘
```

### Security Checklist

- [ ] Enable encryption at rest (S3, RDS, EBS)
- [ ] Enable encryption in transit (TLS 1.2+)
- [ ] Configure VPC with private subnets
- [ ] Enable CloudTrail logging
- [ ] Configure IAM roles with least privilege
- [ ] Enable AWS Config for compliance monitoring
- [ ] Sign BAA with AWS

## Next Steps

After completing this project:

1. **Certification**: Consider ABMGG certification pathway
2. **Advanced Topics**: Somatic variant interpretation, CNV analysis
3. **Automation**: Implement automated ACMG classification
4. **Integration**: Connect to LIMS and EHR systems
